Introduce the Biomarker Consortium platform and highlight resources designed to support biomarker-driven clinical decision-making.
Review current guideline recommendations for biomarker testing in advanced colorectal and gastric cancers, along with recent targeted therapy approvals, with emphasis on BRAF and CLDN18.2.
Apply biomarker testing results to treatment selection and sequencing through interactive, case-based clinical scenarios.
Ask the Expert | Advancing Biomarker-Informed Clinical Practice in GI Cancers: A Focus on BRAF and CLAUDIN18.2
April 11, 2026 • 4:00-5:30 PM PT
Sheraton Grand Los Angeles • Room: California C&F
711 South Hope Street, Los Angeles, CA, 90017
Learning Objectives
Los Angeles
This event is held in partnership with Healthcare Research & Analytics to gain market research insights into health care professionals’ educational needs in their current practice settings.
HRA offers compensation of $300 to oncologists for your consultive contributions during the event discussion, responses to polling questions, and completion of post event survey. Please note that the survey requires your 10-digit NPI or institutional email for verification.
Important Participation Fee Information
To receive your participation fee, you must complete both the post-event survey and the payment verification process within 5 business days of the event.
Please be advised that payments are typically processed within 6–8 weeks post receipt of Survey/Payment Verification.
Incomplete or inaccurate information may result in delays or prevent payment from being processed.
In Partnership with OncLive Biomarker Consortium
Looking for more? We encourage you to explore the OncLive Biomarker Consortium for exclusive access to the latest updates in biomarker testing and targeted therapies.